AbbVie Acquires Landos Biopharma to Enhance Post-Humira Immunology Pipeline

1. AbbVie, the pharmaceutical company, announced on Monday, March 25, 2024, that it has acquired autoimmune startup Landos Biopharma.
2. The acquisition aims to capitalize on an IBD drug developed by Landos Biopharma.
3. This move is part of AbbVie's strategy to strengthen its immunity illness drug pipeline post-Humira era.
4. The announcement was made publicly available through various sources such as Endpoints News, Reuters, LinkedIn posts, and Twitter.